· Published by Health Canada · Official notice
This is duplicated text of a letter from the Hoffmann-La Roche Limited. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
July 29, 2013
Subject: Hepatitis B Virus Recurrence in Patients Treated with RITUXAN® (rituximab): Updated Recommendations for Screening and Management
Hoffmann-La Roche Limited, in consultation with Health Canada, has informed health care professionals of important updates to safety information for RITUXAN.
RITUXAN is a medication that is administered into the veins to treat certain types of cancer (e.g. non-Hodgkin’s lymphoma and chronic lymphocytic leukemia). RITUXAN may also be used to reduce the signs and symptoms of rheumatoid arthritis (RA) and to reduce inflammation associated with severe Granulomatosis with Polyangiitis (GPA), also known as Wegener's Granulomatosis and Microscopic Polyangiitis (MPA). GPA/MPA are disorders that cause blood vessel inflammation.
In the existing prescribing information for RITUXAN, hepatitis B virus screening is recommended for patients at high risk of hepatitis B infection before initiation of treatment with RITUXAN. Roche will be working with Health Canada to update the prescribing information to reflect new recommendations for management of the disease.
Hoffmann-La Roche has sent a letter to healthcare professionals informing them of this important safety information. This information may be obtained on the Canadian website of Hoffmann-La Roche Limited or on the Health Canada website.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of hepatitis B recurrence or other serious or unexpected side effects in patients receiving RITUXAN should be reported to Hoffmann-La Roche Limited or Health Canada.
Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at: 1-888-762-4388
or Fax at: 905-542-5864
or email to: mississauga.drug_safety@roche.com
You can report any suspected side effect associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
Should you have any questions or require additional information regarding the use of RITUXAN, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388 from 8:30 a.m. to 4:30 p.m. Monday to Friday Eastern Standard Time.
original signed by
Lorenzo Biondi,
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited